JPS5813586A - Reserpilinium quaternary salt derivative and antiarrhythmics - Google Patents
Reserpilinium quaternary salt derivative and antiarrhythmicsInfo
- Publication number
- JPS5813586A JPS5813586A JP11341681A JP11341681A JPS5813586A JP S5813586 A JPS5813586 A JP S5813586A JP 11341681 A JP11341681 A JP 11341681A JP 11341681 A JP11341681 A JP 11341681A JP S5813586 A JPS5813586 A JP S5813586A
- Authority
- JP
- Japan
- Prior art keywords
- lower alkyl
- group
- quaternary salt
- substituted
- alkyl group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
【発明の詳細な説明】
本発明は新規なレセルビリニウム第4級塩誘導体および
それを含有する抗不整脈剤Kllする。DETAILED DESCRIPTION OF THE INVENTION The present invention provides novel reservinium quaternary salt derivatives and antiarrhythmic agents containing the same.
本lI@のレセルビリニウム第4級塩誘導体は次〇−欽
式
(式中nr111九+120整数を示し、x%@ 7%
E!l)原子を示し、R1は水素原子11え・i低級
アルキル基を示し%R2はトリ低級アルキルア々ノアy
4エクム基で置換1れそいてもよ一低級アル中ル蓬を示
し、そしてR1は低級アルキル基な示、:。The reservinium quaternary salt derivative of this lI@ has the following 〇-Kin formula (in the formula, nr1119+120 integer, x%@7%
E! l) represents an atom, R1 represents a hydrogen atom, 11 represents a lower alkyl group, and %R2 represents a tri-lower alkyl amonoa.
1 is substituted with 4 equim groups, and R1 is a lower alkyl group, and R1 is a lower alkyl group.
す−、Rjの置換されていてもよい低級アル命ル基o*
′嵩歇(鳩舎によ参存在する置換部分は除く)と絢の低
級アルキル基O真素数と01aは少なくと4s以上であ
る)で表わされる。S-, Rj optionally substituted lower alkyl group o*
It is expressed by the lower alkyl group (O prime number and 01a are at least 4s or more).
誘発−の前記一般式〔I〕で表わされるレセルN9==
りムq!4級塩誘導体は抗不整脈剤として有用な化金物
である。仁Osの化合物としては従来、式
で表わされる14−メチルレセkg 9 !ラム冒−メ
イVが知られて−る(「J、ムm、Oh@m、8oo、
J第aS巻第2507頁(19!!りおよびj*tot
・内弁」第4s係)巻第67頁(197B)参照)、シ
かし′&から、この化金物−抗不整脈作用を有すみか否
か1園
についてe!何等の報告もない。Resel N9 represented by the above general formula [I] of induced-
Rimuq! Quaternary salt derivatives are metal compounds useful as antiarrhythmic agents. Conventionally, the compound of RenOs is 14-methylrece kg 9 !, which is represented by the formula: Ram attack is known (J, Mm, Oh@m, 8oo,
J Volume aS Page 2507 (19!!ri and j*tot
・Refer to "Uchiben" Vol. 4S, page 67 (197B)), from Shikashi'&, this chemical compound - whether it has antiarrhythmic action or not. There are no reports.
本ll@者らは種々研究を重ねえ結果、新規なレセルビ
リニウム第4級塩を得ることに成功し、しかもそれらが
意外にも抗不整脈作用を有することを見出し丸。As a result of various studies, these authors succeeded in obtaining novel quaternary salts of reservirinium, and surprisingly discovered that they have antiarrhythmic effects.
誘発W14に4IAhレセルビ9=ウム第4級塩誘導体
は、一般式
(式中R4は水素原子tたは低級アルキル基を示し、l
lはジ低級アルキルア々)基で置換されていて%X%A
低級アルキル基を示す)で真わ1れ為レセルビly需導
体を例えば、エト四メタン。The induced W14 4IAh reservi 9=um quaternary salt derivative has the general formula (wherein R4 represents a hydrogen atom or a lower alkyl group, and l
l is substituted with di-lower alkyla) group and %X%A
(representing a lower alkyl group) for example, ethotetramethane.
リメチルスル本命シト壜九はジメチルホルムアζV等の
極性博鵬中Ell解1せ、低級アルキルハライド會ll
lI4ルないし大過剰の量で添加して窒素気流中40〜
90℃owivso*度で5〜60時間加熱下に反応さ
せるととにより製造されも反応溶液から目的物質を単離
精製する方法としては例えば、反応後、冷却し、エーテ
ルま九はベンゼン等の比較的非極性の溶媒を添加して。Limethylsul is the preferred choice for the polarity of dimethylformia ζV, etc., and lower alkyl halides.
Add in an amount of lI4 l to a large excess and boil in a nitrogen stream for 40~
A method for isolating and purifying the target substance from the reaction solution is, for example, by reacting it under heating at 90 degrees Celsius for 5 to 60 hours. Add a non-polar solvent.
合成され九本発明の第4級塩を沈殿させ、溶媒と沈殿と
をデカンテーシヨンによ伽分離する。The synthesized quaternary salt of the present invention is precipitated, and the solvent and precipitate are separated by decantation.
得られた沈殿を再び少量のメタノール、エタノール、エ
ト薗メタン、ジメチルスルホキシV11九はジメチルホ
ルムアきド等の比較的極性の高い溶媒Kll解させ、次
いで再度エーテルtえはベンゼン等0@媒を添加して第
4級塩を析出させる。F°別勢によって分離される第4
級塩を1らにアセトン等の溶媒により再結晶させるやと
によ参名らに精製することがで自為。The obtained precipitate is again dissolved in a small amount of methanol, ethanol, methane, dimethyl sulfoxy, dimethyl formamide, or other relatively polar solvent, and then again dissolved in a relatively polar solvent such as ether or benzene. is added to precipitate the quaternary salt. F° 4th separated by another force
It is possible to purify the salt by recrystallizing it with a solvent such as acetone.
本発明のレセルビリニウムII4級塩誘導体Omho検
定は峰ルモットヘOアドレナリン投蔓によって誘発され
る不整脈を阻止するか否かを一定することKよ勤行なわ
れ九、すなわち、体140G 〜600101m4:ル
モy トK 121/に4(Dfyレーンを腹腔内に注
射した後、背位に固定し、外領静臘にカニ島し−シヨン
する。四肢にKOG用電極電極定し心電図を第2誘導に
より観察する。麻酔sO〜60分後にアドレナリンをカ
ニ為−しを通して急速に注入し、生ずる不整脈が25秒
〜60験関持続するようにアVレナダ/量をきめる。注
入アドレナリン量O設定sO分後に供試化金物を徐々に
静注する。供試化合物の静注5分後、10分後、15分
後、SO+11Kbもかしめ設定された量のアドレナリ
ンを急速に注入す、4.5分後、10分11.15分後
Oアドレナリ7II穐不整脈を一度以上完食に阻止しえ
九倶試化會物の量を完食阻孟“′最少有効量(LED
)とする、そのIl定結果は次Oとおりである。The Omho assay of the reservirinium II quaternary salt derivative of the present invention was carried out to determine whether it inhibits the arrhythmia induced by adrenaline injection to the base of Lemotte. After intraperitoneally injecting 4 (Dfy lane) on 121/12, the animal is fixed in the dorsal position and placed in a quiet position in the external area.KOG electrodes are placed on the extremities and the electrocardiogram is observed in the second lead. After ~60 minutes of anesthesia, adrenaline is rapidly injected through the crab tube, and the amount of adrenaline is determined so that the resulting arrhythmia will last for 25 seconds to 60 minutes.The amount of epinephrine to be injected is set and tested after ~60 minutes. Gradually inject the metal intravenously. 5 minutes, 10 minutes, and 15 minutes after the intravenous injection of the test compound, SO + 11 Kb is also caulked, and the set amount of adrenaline is rapidly injected. 4.5 minutes later, 10 minutes 11 .15 minutes later, O adrenaline 7II Arrhythmia can be prevented by completing the meal more than once, and the amount of the 90% test compound can be inhibited by the minimum effective dose (LED).
), the Il constant result is as follows.
アドレナリン不整脈に対する効果
プ■カイ/アiV 80 S15 9
4.41.1・−メイV
ルジ曹−〆イド
上記O供試化合物を前記一般式(IFとO開運において
示すと次のとおpです。Effect on adrenaline arrhythmia Pukai/iV 80 S15 9
4.41.1・-Mei V Rujiso-〆ide The above O test compound is expressed by the general formula (IF and O Kaiun) as follows.
供試化合物 RI R2R111X
ユーーー□ □ −一一一一
ピリエクム一一〆イド
ーダイド
1−メチル−4−n−プロ メチル メチル
プロピル 11ビル−レ鬼ルヒリ凰つム冒
一ダイド
一ダイト
急性−1k (LD5G )は体重的20〜2519の
雄競Yマクスを用いて溶剤K11l解した供試化合物を
尾静臘に注入してリッチフィールド・ウイルコキソノ(
LitchfLe14−WilcoxOn )法によn
ew定され九、前go鎗果から本尭喚に係為新9A′&
レセルビリニウム第4級塩誘導体は既知O化合物よ〉一
層優れえ抗不整脈作用を有する化合物であることがわか
る。Test compound RI R2R111X U□ □ -1111 pyriecum 11〆idodide 1-methyl-4-n-pro methyl methyl
Propyl 11-biru-rekiruhiriri-otsumu-bendai-dite-1k (LD5G) was prepared by injecting the test compound dissolved in solvent K11l into the tail of a male male with a body weight of 20 to 2519. Litchfield Wilcoxono (
LitchfLe14-Wilcox On) method
Ew was determined 9th, and from the previous go Yoshika to Motoya, the new 9A'&
It can be seen that the reservinium quaternary salt derivative is a compound that has antiarrhythmic effects that are superior to known O compounds.
謳造例 1
1−メチに−4−n−プロビルレ竜ル♂リニウム冒−〆
イV
冒−メチルレセルピシy61tニトロメ−ン1s舗Ki
l解し、沃化n−プロピル12mを添加して窒素下80
℃で一夜反応させる0反応原を冷却し九後、攪拌しなが
らエーテル40mを夕景ずつ添加し、析出し九粉末状沈
殿物をFI&し、エタノールから再結晶する。収量60
1(−!L891&)。Synthesis example 1 1-Methyl-4-n-proviral ru♂ linium sterilization V methylreserpicy 61t nitromain 1s store Ki
12ml of n-propyl iodide was added and the mixture was heated under nitrogen for 80°C.
After cooling the reactant, which was allowed to react overnight at ℃, 40 m of ether was added at a time while stirring, and the precipitated powdery precipitate was filtered and recrystallized from ethanol. Yield 60
1(-!L891&).
IR: 1710.1650,110口χ1(芳香族
21() !L4 (−0000H!51)1@(
−oauB 4K) α@ 5 ()kl−(112
(li20jiB sg)町費、:22&0〜22瓜・
℃
元素分析値:
011 III II憾
計算値: 5&40 表04 482夷調値=5五s
7 本s8 472
調造儒 2
4−!l−ゾ■ビルーレセルビリニウム2二(リメナル
ーn−fロVルアン4ニウム)−エチルエステルジ曹−
〆イド
118I(a027−t−ル)02− CQIfa−7
1ノ)−エナルレセルぜリネー)t40slOニトーメ
#yK濤解し、30−の沃化n−プWぜルを一一して窒
素下に80℃で17時間加熱する。IR: 1710.1650, 110 mouths χ1 (aromatic 21() !L4 (-0000H!51) 1@(
-oauB 4K) α@5 ()kl-(112
(li20jiB sg) Town fee: 22&0~22 melon・
°C Elemental analysis value: 011 III II Calculated value: 5 & 40 Table 04 482 adjustment value = 55s
7 Book s8 472 Adjustment Confucianism 2 4-! l-Zovirulecervirinium 22 (limenaru n-froVruane 4nium)-ethyl ester disodium-
〆id 118I (a027-t-ru) 02-CQIfa-7
1)-enalresel gelrine) t40slO Nitome#yK is dissolved, and the iodized n-pW gel of 30- is dissolved and heated under nitrogen at 80 DEG C. for 17 hours.
冷却後、jI応渦◆物を1st1−のエーテルで希釈し
%溶媒をデ会ンテーシw、:イによ)除会す為。After cooling, the mixture was diluted with 1st 1- ether to remove the solvent.
ll&鑞を少量07’タノールKj簿し、攪拌し&がも
100dOエーテルを添加する。生成した粉末る。収量
19g(収率8&2−)@
11:5200,1ア20.1420,1110MMR
: 1 (L? 5 (6) &8 (−0013
11sH)m、p、: 19 !Ls−1911℃前記
各纒造儒に従って次O化金物が舎虞唱れえ。Add a small amount of 07'tanol to the mixture, stir, and add 100 dO ether. The powder produced. Yield 19g (yield 8 & 2-) @ 11:5200, 1a 20.1420, 1110MMR
: 1 (L? 5 (6) &8 (-0013
11sH) m, p,: 19! Ls - 1911℃ According to each of the above-mentioned rules, the following O-chemicals should be recited.
4− n −i vx ヒルーレセルv9ニウム■−メ
イド
IR:5400. 1720.1440. 11001
1MR: 1 to (141) !L75
(−00Hi 411)&9S(芳香m、””2u)
A 85 ()m−@42a4 in)・ ′1゜
m、p、 : 19 &7〜1917℃1−メチルー
4−インプーピルーレセルぜIJLウム璽−ダイV
工R;1700.1620.1100
7.15(芳香族2m) 345(−oooomg
!!i)m、p、: 1741〜17z8℃
4−メチルーレセル11!リニウム2−(トリメチルア
y峰エクム)−エチルエステルジ璽−〆イドXR125
G、1720.14!!0.111011MR: 1
t2 (IHI ) 18 (−001196M
)&95(芳香族21) 五2 (−N(011!I
)l 91)論、p、:1?!7〜199.7℃
元素分析値:
(IIIIHll I4-n-i vx Hirurecell v9nium ■-Made IR: 5400. 1720.1440. 11001
1MR: 1 to (141)! L75
(-00Hi 411) & 9S (fragrance m, ""2u)
A 85 ()m-@42a4 in)・'1゜m, p, : 19 &7~1917℃1-Methyl-4-impupilureselzeIJLumseal-daiV EngineeringR;1700.1620.1100 7 .15 (aromatic 2m) 345 (-oooomg
! ! i) m, p,: 1741-17z8°C 4-methyl-recel 11! Linium 2-(trimethylamine)-ethyl ester distal-end XR125
G, 1720.14! ! 0.111011MR: 1
t2 (IHI) 18 (-001196M
) & 95 (aromatic 21) 52 (-N(011!I
)l 91) Theory, p, :1? ! 7~199.7℃ Elemental analysis value: (IIIHll I
Claims (1)
ン原子を示し、R1・l水素原子または低級ア#中#基
を示し% R2はトリ低級チルキルアミノアン4エク五
基で置換されていてもよい低級アルキル基を示し、そし
て−舎i低級アル命ル鵜を示すが、R10置換されてい
てもよい低級アル中に基O炭素数(場合により存在する
置換部分は除く)とRst)’flk級アルキル基O炭
素数との和は少なくともS以上である)でahされるし
七ルぜリエクム第4級塩誘導飢。 2)一般式 (式中nは1會九は2の整数を示し、!・1twayン
原子を示し%R1は水素原子を九は低級アルキル基を示
し、R1はトリ低級アル命ルアミノアノ峰ニウム基で置
換されていてもよ一低級アルキル基を示し、そしてR1
は低級アルキルaを示すが、Rj4D置換されていても
よい低級アルキル基O炭素数(場合によ)存在する置換
部分会i除く)とガの低級アルキkaの炭素数とOsは
少なくとも3以上である)で表わ1れるレセルビリニウ
ム第4級塩鱒導体を含有すゐことを時機とする抗不整脈
剤。[Claims] 1) General formula (in the formula, 1 is 11 & e is 2t)
% R2 represents a lower alkyl group optionally substituted with a tri-lower tykylaminoane group, and R1 represents a hydrogen atom or a lower atom group; The sum of the number of carbon atoms of the group O in the lower alkyl which may be substituted (excluding the optionally present substituted moiety) and the number of carbon atoms of the Rst)'flk class alkyl group is at least S or more. ) is ahed and seven Ruzeriecum quaternary salt induced starvation. 2) General formula (in the formula, n represents an integer of 2, !-1tway atom, %R1 represents a hydrogen atom, 9 represents a lower alkyl group, R1 represents a tri-lower alkyl aminoamine group) represents a lower alkyl group optionally substituted with
represents lower alkyl a, Rj4D optionally substituted lower alkyl group O carbon number (excluding optional substituent group i), lower alkyl ka carbon number and Os are at least 3 An antiarrhythmic agent containing a reservirinium quaternary salt trout conductor represented by (1).
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP11341681A JPS5813586A (en) | 1981-07-20 | 1981-07-20 | Reserpilinium quaternary salt derivative and antiarrhythmics |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP11341681A JPS5813586A (en) | 1981-07-20 | 1981-07-20 | Reserpilinium quaternary salt derivative and antiarrhythmics |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS5813586A true JPS5813586A (en) | 1983-01-26 |
JPH0217553B2 JPH0217553B2 (en) | 1990-04-20 |
Family
ID=14611697
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP11341681A Granted JPS5813586A (en) | 1981-07-20 | 1981-07-20 | Reserpilinium quaternary salt derivative and antiarrhythmics |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS5813586A (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4935400U (en) * | 1972-06-30 | 1974-03-28 | ||
JPS5113799A (en) * | 1974-07-22 | 1976-02-03 | Nisshin Flour Milling Co | RESERUPIRIN JUDOTAINO SEIZOHO |
JPS5293799A (en) * | 1976-02-02 | 1977-08-06 | Nisshin Flour Milling Co Ltd | Recerpine derivatives and antiarryhythics |
JPS5510595A (en) * | 1978-06-09 | 1980-01-25 | Rolex Montres | Electronic timer for submarine use |
-
1981
- 1981-07-20 JP JP11341681A patent/JPS5813586A/en active Granted
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4935400U (en) * | 1972-06-30 | 1974-03-28 | ||
JPS5113799A (en) * | 1974-07-22 | 1976-02-03 | Nisshin Flour Milling Co | RESERUPIRIN JUDOTAINO SEIZOHO |
JPS5293799A (en) * | 1976-02-02 | 1977-08-06 | Nisshin Flour Milling Co Ltd | Recerpine derivatives and antiarryhythics |
JPS5510595A (en) * | 1978-06-09 | 1980-01-25 | Rolex Montres | Electronic timer for submarine use |
Also Published As
Publication number | Publication date |
---|---|
JPH0217553B2 (en) | 1990-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE2709820C2 (en) | N- (mercaptoacyl) -L or DL-cysteines, processes for their preparation and mucolytic agents containing these compounds | |
US4383994A (en) | Homocysteine thiolactone salts and use thereof as anti-neoplastic agents | |
US3228833A (en) | Anticoccidial compositions and methods of using same | |
JPS5869812A (en) | Blood sugar level depressing agent | |
SE436027B (en) | NEW ESTARS OF QUARTERLY AMMONIUM SALTS WITH ANTICOLINERG ANTI-SECRETARY EFFECT AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE SALTS | |
EP0186252A2 (en) | Use of thiophene compounds for the manufacture of a medicament against tumours | |
CA1240326A (en) | 2-(.omega.-ALKYLAMINOALKYL)-AND 2-(.omega.-DIALKYLAMINOALKYL)- 3-(4-X-BENZYLIDEN)-PHTALIMIDINES | |
EP0008802B1 (en) | Ergoline derivatives, their preparation and therapeutic composition containing them | |
US3923994A (en) | Anti-arthritic compositions comprising a 3-aryl 2-thiohydantoin and methods of producing anti-arthritic acitvity | |
JPS5813586A (en) | Reserpilinium quaternary salt derivative and antiarrhythmics | |
DE2235935A1 (en) | NEW DERIVATIVES OF TRIIODIZED AMINOBENZENE CARBONIC ACIDS, A PROCESS FOR THEIR PRODUCTION AND THEIR USE | |
CA1112648A (en) | 2-[3,4-disubstituted-phenylimino]-imidazolidines | |
JPS58219115A (en) | Veterinary drug for inhibiting growth of virus infectious disease | |
NZ204589A (en) | 3-(n,n-dimethylcarbamoyl)-pyrazolo(1,5-a)pyridine and pharmaceutical compositions | |
JPS6041670B2 (en) | 2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid ester and its manufacturing method | |
KR860000103B1 (en) | Process for preparing 3'-substituted-5'-(2-amino-4-pyridyl)-1',2'4'-triazoles | |
JPS63255268A (en) | Dopamine-beta-hydroxylase inhibitor | |
PT86513B (en) | PREPARATION PROCESS OF DOPAMINE-BETA-HYDROXYLASE INHIBITORS | |
JPS588016A (en) | Cardiotonic drug | |
US3067097A (en) | Anti-turkey blackhead compositions of 1-ethyl-3-methyl-3 (5-nitro-2-thiazolyl) urea and method of using same | |
GB2068963A (en) | Basic ethers of 4-hydroxy-benzophenones acting as beta-blocking agents and relevant preparation processes | |
JPS61260018A (en) | Anti-allergic agent | |
SU1001855A3 (en) | Process for preparing 2-substituted-1h-phenanthro(9,10-d)imidazo or their salts | |
EP0008950A3 (en) | Pyrimido(1,6-a)indole derivatives and intermediates therefor, processes for their preparation, pharmaceutical compositions containing the derivatives and their use | |
JPS5936696A (en) | 2'-deoxy-5-substituted uridine derivative, its preparation and antitumor agent containing it |